AIIMS Bhopal

रोगी संबंधी किसी भी शिकायत के लिए grievance@aiimsbhopal.edu.in पर ईमेल भेजें।
एम्स, भोपाल में कोविड-१९ महामारी के दौरान देहदान करने के लिए सूचना
कोविड टीकाकरण से किसी भी प्रकार का प्रतिकूल प्रभाव होने पर कृपया aefi@aiimsbhopal.edu.in पर संपर्क करें
ऐसे दलालों एवं धोखेबाजों से सावधान रहें जो या तो अपने प्रभाव या अनुचित साधनों की सहायता से एम्स भोपाल में नौकरी दिलाने का मिथ्या वादा कर धोखा देने का प्रयास करते हैं
For any communication related to SC/ST matters, please contact on lo_sc_st@aiimsbhopal.edu.in.
एम्स भोपाल में कार्य ग्रहण करने हेतु रिपोर्ट करने वाले कर्मचारियों के लिए दिशानिर्देश

2nd Convocation of AIIMS Bhopal on 02 April, 2023

माननीय केन्द्रीय मंत्री

डॉ. मनसुख मांडविया, माननीय केन्द्रीय मंत्री
स्वास्थ्य एवं परिवार कल्याण मंत्रालय और रसायन और उर्वरक मंत्रालय, भारत सरकार

माननीय राज्य मंत्री

डॉ. भारती प्रवीण पवार, माननीय राज्य मंत्री
स्वास्थ्य एवं परिवार कल्याण मंत्रालय, भारत सरकार

नया क्या है

28-March-2023
Interview Schedule: Rolling Advertisement for Recruitment to the Post of Senior Residents (Non-academic) Purely on Temporary Basis at AIIMS Bhopal

28-March-2023
Advertisement for recruitment to the post of Junior Residents (non-academic) on contractual basis at AIIMS Bhopal

27-March-2023
AIIMS Bhopal Alumni event invitation - 1st April 2023

25-March-2023
Recruitment for the posts on a purely contractual basis (up till the duration of project) for the CSAM & AMB Project.

23-March-2023
Recruitment of Contractual Staff in ICMR funded Extramural Project ""A Multicentric, Clinico-epidemiological Study to Enhance Diagnostic Capacity for Melioidosis in Madhya Pradesh”.

22-March-2023
Details of 2nd convocation of AIIMS Bhopal to be held on 02 April, 2023

20-March-2023
Corrigendum: Recruitment advertisement for Student Internship under the Scientific Social Responsibility Policy in SERB funded project

18-March-2023
ROLLING ADVERTISEMENT FOR RECRUITMENT TO THE POST OF SENIOR RESIDENTS (NON-ACADEMIC) PURELY ON TEMPORARY BASIS AT AIIMS BHOPAL

17-March-2023
Result : Recruitment of Smart Unit Staff in RCoENRRT

17-March-2023
Advertisement for Group B Non Faculty posts of Deputation basis

17-March-2023
Result : Recruitment of Junior Research Fellow in an ICMR-funded research project titled - Understanding the mechanism for aberrant expression of Sphingosine Kinase 1 in oral squamous cell carcinoma

15-March-2023
Result: Notification for non-academic senior residents interview on 28.02.2023 under rolling advertisement

14-March-2023
Recruitment advertisement for Student Internship under the Scientific Social Responsibility Policy in SERB funded project

14-March-2023
Rolling recruitment notification for Group-A faculty posts on direct recruitment basis at AIIMS Bhopal

14-March-2023
Interview Schedule: Notification for non-academic senior residents interview on 15.03.2023 Rolling advertisement for recruitment to the post of senior residents (non-academic) purely on temporary basis at AIIMS Bhopal

10-March-2023
Addendum : Rolling Notification for Group "A" Non-Faculty Recruitment on Direct Recruitment Basis

09-March-2023
Recruitment of Contractual Staff in ICMR funded extramural project “Clinicopathological and molecular and profiling of adult and paediatric cases of membranous nephropathy”

07-March-2023
Addendun to recruitment notification no. Admin/AIIMS/Bhopal/2022 Dated 14/05/2022

04-March-2023
Result: Recruitment under the KRG project

03-March-2023
Result : Recruitment of Lab Technician in ICMR funded extramural project “Setting up of registry for renal complications in Indian children with Sickle Cell Disease: The Indian Sickle Cell Nephropathy (ISN) Consortium” on Contract Basis

03-March-2023
Notification for non-academic senior residents interview on 15.03.2023 Rolling advertisement for recruitment to the post of senior residents (non-academic) purely on temporary basis at AIIMS Bhopal

01-March-2023
Result: Recruitment of Contractual Staff in ICMR funded Extramural Project "MISSION: A multicentric capacity building initiative to strengthen the clinical and laboratory detection of melioidosis in India with special focus on the north eastern states".

01-March-2023
Result: Recruitment of Contractual Staff in DHR-ICMR funded project “Pan India Epidemiological, Virological and Genomic Surveillance for Human Influenza and COVID-19 through VRDL Network”

27-Feb-2023
Interview Schedule: Notification for non-academic senior residents interview on 28.02.2023 under rolling advertisement

27-Feb-2023
Final list of Eligible, Provisionally Eligible and Not Eligible Candidates against Rolling Notification for Group A Faculty Posts on Direct Recruitment Basis dated 14.05.2022

27-Feb-2023
Result: Walk-in-interview for the Posts of Assistant Professor on Contractual Basis in Various Departments at AIIMS Bhopal

24-February-2023
Stray Vacancy round for MD/MS Courses January 2023 Session.

22-February-2023
SPOT counselling for DM/MCh Courses January 2023 Session

22-February-2023
Advertisement for recruitment to the post of junior residents (non-academic) on contractual basis at AIIMS Bhopal

22-February-2023
Result: Recruitment of Consultant (Molecular Biology) in NIH-funded Research Project titled “Improving Outcomes in Depression in Primary Care in a Low Resource Setting”

माननीय अध्यक्ष, एम्स भोपाल

प्रो. (डॉ.) योगेंद्र कुमार गुप्ता
माननीय अध्यक्ष, एम्स भोपाल

कार्यपालक निदेशक, एम्स भोपाल

प्रो. (डॉ.) अजय सिंह
कार्यपालक निदेशक, एम्स भोपाल

कैलेंडर

Closed Holiday

Restricted Holiday

Tweets by AIIMSBhopal

Our Services

Poison Information Center

Grievance

Press Release

Profile:
The present Director of All India Institute of Medical Sciences, Bhopal, Prof. Sarman Singh was born to the inerudite parents hailing from a very small village of Aligarh, Uttar Pradesh. He did his MBBS from prestigious King George’s Medical College, Lucknow, MD from Post Graduate Institute of Medical Research (PGIMER), Chandigarh, and Postgraduate course in Epidemiology of Infectious Diseases from world famous University of Michigan at Ann-Arbor, USA and a course on International Research Ethics from Harvard University, USA and Natal University, South Africa. He has been working at the All India Institute of Medical Sciences, New Delhi since 1988 at various positions.

Dr. Singh is an able administrator and hard task master and has good administrative and constitutional knowledge. He is now internationally acclaimed medical scientist with outstanding research and academic achievements.

He has guided more than 20 PhD and MD students. Of the 15 PhD students, all are pursuing their career successfully – 7 in the USA, 2 in South Korea, 2 in the UK, 1 in Germany and 8 in India. All have received accolades in the form of best poster or best oral presentations in various national and international conferences and most of them have received travel awards from DST, DBT, ICMR, BMGF or from conference organisers. One student was selected by HIV trust fund (Geneva) to work at NIH for 6 months.

His team received several research grants from Department of Biotechnology, Indian Council of Medical Research, Department of Science, and Technology, Council for Scientific and Industrial Research, NIH (USA), DFID, European Commission, Bill & Melinda Gates Foundation, WHO etc.
Dr. Singh is voracious writer, dedicated researcher, loved teacher by his students, an able administrator, and a visionary. This is evident from his high citation index of 7400, i10 index of 143 and h-index of 42.

The main focus of Prof. Sarman Singh’s research has been on developing more sensitive and cost-effective diagnostic methods for infectious diseases, particularly those that are difficult to diagnose and treat. Towards this goal, he has made several ground breaking discoveries in the field of pathophysiology of visceral Leishmaniasis or kala-azar. He was the first to develop and patenting a rapid and highly cost-effective diagnostic test for this disease. A novel recombinant antigen (Ld-KE16) was prepared from an Indian strain of L. donovani (Singh & Sivakumar 2003; Sivakumar et al, 2006) ((PCT/IN2003/000400) and the commercial rights of the test were transferred to the M/s Span Diagnostic Pvt Ltd through the Department of Biotechnology, Govt. of India. The company has made rapid diagnostic test (RDT) kits in various test formats, which were dedicated to the nation by the Honourable Minister of Science & technology, Government of India Shri Kapil Sibal on February 6, 2006 in a glittering ceremony at the Press Club of India. These RDTs have made the invasive and hazardous methods like bone marrow and splenic aspiration dispensable at a very affordable price (Singh 2006). It is a matter of pride that the diagnosis of kala-azar can now be made at a cost of less than Rs. 50 per patient in India using these trailblazing “Made in India” kits. These test kits are exceptionally accurate with 100% specificity and 98% sensitivity.

The disease kala-azar mainly affects the poor and down-trodden section of our society (Singh et al, 2000). Till rapid tests were made available, thousands of poor in the states of Bihar, W Bengal and Uttar Pradesh were dying due to this disease because of non-availability of sensitive, cost-effective and point-of-care diagnostic methods. It may be mentioned that with the availability of this revolutionary test, the number of kala-azar deaths has come down significantly - thanks to the Government of India for their active surveillance, and free treatment combined with the RDT kit developed by Dr. Singh that played a pivotal role in the national kala-azar elimination program. This cutting edge technology is also saving of millions of dollars of the Indian Government every year on foreign exchange. This is the first ever-indigenous invention by a medical scientist, which has become an integral part of any national disease elimination programme. This invention received high appreciation and applauds from the WHO (WR-India, as chair of the award selection committee) in the BMJ Research and Innovation excellence award distribution ceremony while announcing the award to Dr. Sarman Singh.

Beside the above, this work has been recognised by the prominent science agencies of India, notably the Department of Biotechnology (Product, process and Commercialisation award); Indian Council of Medical Research (Dr. BK Aikat Award); Medical Council of India (Dr. BC Roy Award); Government of Uttar Pradesh (Vigyan Ratna Award); Indian Medical Association (Med-Achiever Award); Delhi Medical Association (Chikitsa Ratna Award); Indian Society of Parasitology (Dr. BP Pandey Oration Award); Indian Association of Tropical Parasitology (Outstanding Researcher in Parasitology); Indus Foundation (Innovation Excellence Award); Society for Immunology and Immunopathology (Life Time achievement Award) and many more.

The issue of reservoirs of visceral leishmaniasis in India has remained dogmatic. The dictum has been that only post-kala-azar dermal leishmaniasis (PKDL) patients serve as reservoirs and there are no animal reservoirs in India, in contrast to the well-known animal reservoirs worldwide. In a spearheading study Dr. Singh working on the premise that in several areas where there are no PKDL cases (Dey et al, 2007), the outbreaks or sporadic cases of VL do occur (Singh et a, 2011). Furthermore, using novel PCR primers (PCT/IN2004/000395) his team also found that VL and PKDL strains are genetically different and both strains have differences in the anti-leishmanial drug susceptibility pattern (Mishra et al 2011). Therefore, in a radical approach, his team investigated thousands of animals in endemic areas as well as in non-endemic areas and found that goats are very potent animal reservoirs of VL in India (Singh et al 2013). These findings are bound to make drastic deviation in the kala-azar elimination programme of India.

The whole genome sequence (WGS) of several isolates of Leishmania donovani from VL patients has been sequenced, but it is a matter of pride that Dr. Sarman Singh became the first in the world to carry out the WGS of the PKDL strain of Leishmania. The sequence alignment data showed significant differences in the genome of PKDL strain as compared to VL strains (Gupta et al, 2015). The WGS also revealed a revolutionary finding that a major portion of a saprophytic bacterial (Parvibaculum lavamentivorans DS-1) genome gets integrated into the genome of PKDL strain. On the basis of this discovery new biological phenomenon has been postulated, thereby this integration could be the triggering factor to manifest the two strains differently (the viscerotropic form becoming dermotropic). This landmark discovery also proved his old hypothesis, that Leishmania donovani undergoes in-vivo hybridization to manifest as PKDL. These findings will go a long way in the eradication of old dogma about PKDL.

India has distinction of having maximum cases of HIV, TB, and Leishmaniasis. In an in-depth invited review in International Journal of Infectious Diseases Dr. Singh discusses the current scenario of HIV-leishmania co-infection and factors that contributed to help quell this duo, in contrast to the other co-endemic countries (Singh, 2014). However, the Leishmania and TB both are co-endemic in several parts of eastern India. It is also known that approximately 20% VL patients will have concomitant or subsequent Tuberculosis but there is no effective vaccine for these infections. Considering this as a major research challenge, for the first time his team prepared a self-cleaving chimeric DNA vaccine which can be used against both TB and visceral leishmaniasis (Dey et al, 2008). This cutting edge innovation has been patented globally (PCT/IN2009/000093). The department of Biotechnology who funded and licensed this work, observed this invention as of high commercial value. The reputed journal Vaccine invited him to publish this innovative research to publish in their special issue (Dey & Singh, 2009) and again another reputed journal (Parasites and Vectors) invited him to write a systemic review on Leishmania vaccines (Srivastava et al 2015).
Miltefosine is a new drug approved for the treatment of VL in 2004 only but within few years of its introduction, the efficacy has gone down. To understand the mechanism of resistance, in an avant-garde study his team has discovered novel mutations in the genes of Leishmania; which impart resistance to miltefosine. These mutations can now be used as molecular markers to diagnose and predict miltefosine resistance in circulating strains at an initial stage (Srivastava et al, 2016).

Tuberculosis is the main killer infectious disease in India. On the top of that multi-drug resistant (MDR) and extensively drug resistant (XDR) forms have emerged forcing WHO to announce MDR-TB as health emergency. Dr. Singh for the first time reported high incidence of XDR-TB in Indian AIDS patients (Singh et al 2007). Though this publication created lot of discussion in Government, but finally it was accepted as realty and based on these findings Government of India implemented programmatic management of DR-TB (PMTD). Unfortunately early and accurate diagnosis of TB has remained a major challenge for researchers and programme managers. In last 20 years several serological test kits were dumped in the Indian market for the diagnosis of PTB and EPTB. But these kits gave highly inaccurate results, leading to unnecessary treatment to hundreds of thousands of patients, and leaving several thousands TB patients untreated. Dr. Singh played crucial role in getting these serological kits banned for import, manufacture and use in India (The Independent, UK; Times of India; The Hindu; Deccan Herald; Spectrum; etc.) and live discussion on the all India Radio. The Editorial published in the IJMR (Singh & Katoch, 2011) played the key role in this decision taken by the Government of India in May 2012.

However, the ban on serology has created a complete gap in the TB diagnostic field. Dr. Singh worked untiringly to find out novel molecular tools and biomarkers for the diagnosis and differentiation of drug susceptible and drug resistant Mycobacterium tuberculosis. His laboratory has recently made a revolutionary discovery in this field. After screening hundreds of proteins of MTB, his team identified 5 novel proteins/antigens, which are over-expressed only during the in-vivo drug resistance development. The genes were cloned and proteins expressed, purified and used on various categories of patients showing the sensitivity and specificity of these proteins between 98.2% -100% and 89.1 - 98.2%, respectively (Singh et al, 2015, Singh et al, 2016*). Using these novel proteins development of a point-of-care (POC) rapid test is underway. This innovation will be a game changer in the area of TB diagnostics not only for India but globally. The Foundation for Newer Innovative Diagnostics (FIND) has shown interest in this innovation and very soon this innovation will make India proud of innovative research. He has also used his epidemiological skills acquired during his training at University of Michigan (USA) and has done various field studies. He has formed a network of scientists working on Tuberculosis in India. In a spearheading study his team screened 628 isolates of MTB collected from various parts of the country, genotyped these and did drug susceptibility testing to uncover how the socio-geographical factors influence the prevalence of various genotypes of MTB. This was unique and first study of its kind. The Beijing genotype of MTB, which is most prevalent in NER-India is having highest vulnerability for drug resistance while EAI genotype (found mainly in South India) having least preponderance for drug resistance (Singh et al, 2015). In this study he for the first time successfully documented the impact of population migration on the prevalence of various mycobacterial genotypes in different. This study was judged as the best study of 2015-16 carried out at the AIIMS and Dr. Singh was awarded First Prize in Research Excellence by the hon’ble Minister of Health and Family welfare, Government of India, Sri JP Nadda. The study has got wide coverage in the print media and Department of Biotechnology (NER-BPMC) has announced a special call for proposals to deal with this menace. Recently his team proposed to make use of phantom drones to control drug resistant tuberculosis in North-East Region of India. The proposal is being actively considered by the central TB division of Ministry of Health & Family elfare, Government of India.
Dr. Singh has also done pioneering work in the field of non-tuberculous mycobacteria (NTM) often neglected by clinicians and medical microbiologists as contaminants. In AIDS era these NTM have gained much importance but the conventional methods of identification are neither reproducible nor very specific. His team has developed novel sets of multiplex-PCR primers for the diagnosis and differentiation of Mycobacterium tuberculosis, M. avium, M. kansasii, and other NTM, directly from the clinical samples in a single tube (PCT/IN2004/000396). These PCR primers and the process have been found highly sensitive and specific and are being routinely used at AIIMS and many other laboratory settings throughout the country (Singh et al, 2006, Gopinath et al, 2009, Kumar et al 2014a). The PLoS Neglected Tropical Disease published Dr. Singh’s “Personal Opinion: on this subject, which is highly cited. This has made a paradigm shift in the understanding of NTM disease in India. Using the same gene targets, a new technology known as loop mediated isothermal amplification (LAMP) assay has also been developed by him with a commercial partner (Kumar et al, 2014b). The technology is being evaluated across the country and soon may be taken up by the Government of India. Currently molecular tools have become essential to understand the pathophysiology and drug targets. Dr. Singh has moved with the time. His laboratory is equipped with all modern tools including 6-laser flow cytometer and New Generation Sequencer (NGS), beside all routine diagnostic tools and services. His laboratory caters diagnostic (routine and specialised) tests with precision and accuracy. For his quality services his laboratory is recognised as training centre for whole Asia region for new TB diagnostics by the Stop-TB division of WHO (Geneva) and also by the central TB division of Government of India.
Prof. Singh is the sole authority in the field of Toxoplasmosis in India for both medical and veterinary fraternity. His Toxoplasma reference laboratory is the only centre in entire India, which is maintaining and distributing the Toxoplasma gondii strains to other researchers for the last 26 years continuously. Because of his spearheading teachings through webinars, print media and on other platforms including the FOGSI, ISP, IATP, IAMM, etc he has been able to convince the majority of Gynaecologists, Obstetricians, Paediatricians and Medical /veterinary microbiologists of India, that bad obstetric history (BOH) is a misnomer and that Toxoplasma causes multiple abortions is only a myth (Singh 2003; Singh & Pandit 2004; Singh et al, 2014). He is now the last word for Gynaecologists and Obstetricians of India regarding the diagnosis and management of congenital/antenatal toxoplasmosis. He has saved several unwarranted terminations of precious pregnancies suspected to have intrauterine toxoplasmosis on the basis of inaccurate test methods. His work has been cited in several reputed reference and text books-notably, the Infectious Diseases of foetus and neonates (Remington & Klein), Practical Obstetric Problem (Ian Donald); Toxoplasmosis: A comprehensive Clinical Guide (David et al), International Encyclopaedia of Public Health (Academic Press); Practical Guide to high-risk Pregnancy and delivery (Arias); Internal Medicine: an Illustrated Radiological Guide (Tubaikh) to name a few. It is worth mentioning that for his work on Toxoplasmosis he has been honoured by the Indian Academy of Tropical Parasitology as well as by the Indian Society of Parasitology. Beside TORCH infections his original work on mother-to-child transmission of Hepatitis E virus has been cited in almost all text books of paediatrics and Obstetrics, for examples – Principles and Practice of Infectious Diseases (Bennett et al); Infectious Diseases of foetus and neonates (Remington & Klein); Practical Obstetric Problem (Ian Donald); Viral Infections of Humans (Kaslow et al) and Avery’s Neonatology.

He was the first to document first case of HIV-Leishmania co-infection in India (Singh et al 2000a) and also high incidence rates of hepatitis B and Hepatitis C virus infections in Kala-azar patients of Bihar who were receiving multiple injections of sodium antimony gluconate (Singh et al, 2000b). He for the first time documented that circumcised patients had lower incidence of Hepatitis C and HIV virus infections in India. The WHO noticed these findings and its Safe Injection Global Network (SIGN) division organised a special meeting with Government of India (in 2001) and highlighted the need for safe injection practices in India. Dr. Singh was special invitee in this meeting to present his findings. This advisory issued by the WHO to India based on his findings changed the scenario of injection practices in India.

As a physician also he has contributed immensely in the Clinical Practice. For the first time from India, he reported mucosal involvement by Leishmania donovani in an AIDS patient and Prof. Singh coined a new clinical condition- post-kala-azar mucosal leishmaniasis (PKML) and published in the Lancet (Singh, 2004). Other authors are now using this clinical term also (Singh 2014). He has treated rare clinical conditions like genitourinary enterobiasis (Singh et al, 1989), Scalp Phthiriasis (Singh et al, 1990), Hookworm granuloma of Gastric Os (Singh 1999), Toxoplasmosis in an immunocompetent surgeon, and many more. He has successfully carried out clinical trials of herbal immunomodulators in AIDS patients. He is running a pre- and post-test counselling clinic for HIV/AIDS and TORCH infections for the last 20 years and supervises more than 5 lakh investigations each year.

Indeed Dr. Singh has several firsts to his credit, whether it pertains to new discoveries, novel innovations, finding new pathogens, clinical conditions, or disease manifestations. His keen interest in new discoveries and scientific dissemination started from his early residency days at PGIMER, Chandigarh. Dr. Singh was the first to report fungal contamination (Trichosporon beigelli) of UGI endoscopes instead of routine decontamination procedures (Singh et al 1989). This work has been cited in almost all textbooks of Gastroenterology. He also reported new species of Trichuris (vulpis) in Onges tribes of Nicobar (Singh et al 1993) and new genotypes of Mycobacterium tuberculosis in India.

In addition to research, teaching and patient care he is helping various Government organizations like UPSC, DBT, ICMR, ICAR in the academic and administrative processes, and on being on their task forces. Dr. Singh has been member of Peer Team of NAC and Inspector of the MCI. Dr. Singh has also been on the research advisory committees/examiner of more than 25 central and state universities. He is also member of scientific advisory committees of JIMPER, Pondicherry; RMRC, Jodhpur and National JALMA Institute for Tuberculosis. He is grant reviewer for DST, DBT, DHR, ICMR, CSIR, BIRAC/IKP, BCIL of India. His research is also recognised outside India and he is grant reviewer for Medical Research Council, Government of South Africa; Ministry of Science and Technology, Life Sciences Division, Government of Israel and Ministry of Health (General Director for Scientific Research and Health Innovation), Italy. He is also abstract reviewer for World AIDS conference (IAS, Geneva) consecutively for 9th year and also for CROI (USA) and ICASA (South Africa) for last 3 years.

He is one of the upper 10% peer reviewers of publications from topmost publishers like Elsevier (including Lancet), NPG, Bentham, Springer, ASM, JAMA, BMA and others. Overall he is manuscript reviewer for 41 reputed journals while refusing review requests from hundreds of online journals.

वर्ष 1956 में नई दिल्ली में अखिल भारतीय आयुर्विज्ञान संस्थान (एम्स) की स्थापना देश के प्रथम प्रधानमंत्री श्री जवाहर लाल नेहरू की महत्वाकांक्षी परियोजना थी और इसे देश की प्रथम स्वास्थ्य मंत्री श्रीमती राज कुमारी अमृत कौर ने संसद में अधिनियम (एम्स, अधिनियम) के माध्यम से पूरा किया। तथापि, पिछले 50 वर्षों में यह महसूस किया जा रहा था कि ऐसी तृतीयक स्तर स्वास्थ्य सेवाओं की उपलब्धता में भारी क्षेत्रीय असंतुलन था जो किफ़ायती होने के साथ-साथ विश्वशनीय हो, देश में क्षेत्र विशेष के अनुकूल बड़ी संख्या में डॉक्टरों की उपलब्धता एवं अनुसंधान गतिविधियों के संचालन से उपलब्ध चिकित्सा सुविधाओं में सुधार करते हुए गुणवत्तायुक्त चिकित्सा सुविधा उपलब्ध कराने में सक्षम हो। वर्ष 2003 में श्री अटल बिहारी वाजपेयी, तत्कालीन प्रधानमंत्री द्वारा एम्स, नई दिल्ली के तर्ज पर देश के विभिन्न भागों में 6 नए एम्स संस्थान स्थापित करने की परिकल्पना की गई। वर्ष 2006 में स्वास्थ्य एवं परिवार कल्याण मंत्रालय, नई दिल्ली के अन्तर्गत प्रधानमंत्री स्वास्थ्य सुरक्षा योजना (पी.एम.एस.एस.वाई.) के अंतर्गत भारत सरकार द्वारा शुरू की गई पहल के माध्यम से राष्ट्रीय महत्व के संस्थान एम्स, भोपाल की आधारशिला रखी गई। एम्स, भोपाल 2012 में आरंभ हुआ तथा 960 बिस्तरों की क्षमता के साथ सुपर स्पेशियलिटी अस्पताल के रूप परिकल्पित किया गया।
जब दिनांक 04.06.2018 को मैंने संस्थान में कार्य ग्रहण किया था तब मैंने संस्थान को तीनों क्षेत्रों अर्थात शैक्षणिक, अनुसंधान एवं रोगी देखभाल सेवा में उत्कृष्ट बनाने का संकल्प किया था। मैंने यह भी ध्यान रखा कि संस्थान में रोगी देखभाल सेवाओं को बढ़ाने तथा भर्ती प्रक्रिया, क्रय तथा अन्य सेवाओं में पारदर्शिता रहे। मुझे आपके साथ यह साझा करते हुए खुशी हो रही है कि मेरे द्वारा दिए गए उपर्युक्त आश्वासनों को पूरा करने में काफी हद तक मैं सफल रहा हूँ। यह अपने संकाय सदस्यों, अधिकारियों, रेजीडेंट चिकित्सकों, नर्सिंग अधिकारियों, प्रशासन, वित्त तथा अभियांत्रिकी एवं अन्य स्टाफ, छात्रों तथा सबसे महत्वपूर्ण मेरे सचिवालय के सहयोग के अभाव में संभव नहीं हो सकता था। हमने अनेक उपलब्धियां हासिल की है। बेशक संख्या में यह कम है लेकिन आंकड़ों में ये व्यापक है।

एम्स, भोपाल 150 एकड़ में फैला एक विशाल संस्थान है जिसमे अस्पताल परिसर, आवासीय परिसर, छात्रावास, चिकित्सा महाविद्यालय, नर्सिंग कॉलेज,(अत्याधुनिक नर्सिंग शिक्षा) तथा अन्य आवश्यक सेवाएँ संस्थापित है। वर्तमान में अस्पताल सेवाओं में 24 मॉड्यूलर ऑपरेशन थिएटर सहित बिस्तरों की कुल क्षमता 793 है। 42 कार्यात्मक विभागों जिसमें 22 स्पेशलिटी, 14 सुपर स्पेशलिटी शामिल है तथा 6 अन्य विभागों में प्रत्येक माह ओपीडी में लगभग 46264 तथा आईपीडी में 1609 रोगियों का उपचार किया जाता है। एम्स, भोपाल में निश्चेतन विज्ञान, जीव रसायन, सामुदायिक एवं परिवार चिकित्सा, दंत विभाग, डर्मोटोलाजी, डाइटेटिक्स, आपातकालीन चिकित्सा, जनरल मेडिसिन, जनरल सर्जरी, माइक्रोबायोलाजी, प्रसूति एवं स्त्री रोग विभाग, नेत्र रोग विज्ञान, ऑर्थोपेडिक्स, ओटोरहिनोलार्योलाजी, (ईएनटी-हेड एंड नेक सर्जरी) पीडियाट्रिक्स, पैथोलाजी, भौतिक चिकित्सा एवं रिहैबिलिटेशन, साइकेट्री, रेडियो-डायग्नोसिस एंड इमेजिंग, रेडियोथैरेपी, ट्रामा एवं आपातकालीन चिकित्सा, ट्रांसफ्यूजन मेडिसिन एवं ब्लड बैंक एवं आयुष की सुपर स्पेशलिटी सेवाएं उपलब्ध है। सुपर-स्पेशियलिटी सेवाओं में बर्न एंड प्लास्टिक सर्जरी, कार्डियोलाजी, कार्डियोथोरेसिक सर्जरी, एंडोक्रिनोलाजी एंड मेटाबालिज्म, नेफ्रोलाजी, न्यूरोलाजी, न्यूरोसर्जरी, नियोनेटोलाजी, न्यूक्लियर मेडिसिन, पीडियाट्रिक सर्जरी, पल्मोनरी मेडिसिन एंड टीबी, सर्जिकल गैस्ट्रोएंट्रोलाजी, सर्जिकल ऑन्कोलाजी, यूरोलाजी एवं एनाटामी का टीचिंग विभाग, फोरेंसिक मेडिसिन एंड टोक्सिकोलाजी, फार्माकोलाजी, फिजियोलाजी, अस्पताल प्रशासन एवं नर्सिंग कॉलेज शामिल है। हाल ही में एक नए ट्रांसलेशनल मेडिसिन विभाग की स्थापना भी की गई है। जो देश में अद्वितीय है। एम्स भोपाल में आयुर्वेद, योग एवं प्राकृतिक चिकित्सा, यूनानी, सिद्ध एवं होम्योपैथी सहित आयुष विभाग भी है। एम्स, भोपाल के निर्मित भवन में 135 ब्लॉक है।

एम्स, भोपाल से देश हित में विशिष्ट प्रतिभा को स्थान देने, चिकित्सा एवं पैरा मेडिकल में उच्च प्रशिक्षित मानव संसाधन उपलब्ध कराने तथा राष्ट्रीय एवं क्षेत्रीय स्वास्थ्य हितों में अनुसंधान कार्य करने की अपेक्षा है। संस्थान चिकित्सा शिक्षा में नवाचारों के साथ प्रयोग की अनुमति देता है। एम्स, भोपाल अपने चिकित्सा महाविद्यालय एवं नर्सिंग कॉलेज के माध्यम से कुल 9 पाठ्यक्रमों का संचालन कर रहा है। इन पाठ्यक्रमों में एमबीबीएस, एमएस, डीएम, एमसीएच, पीडीसीसी, पीएचडी एवं बीएससी नर्सिंग (आनर्स) तथा एमएससी (नर्सिंग) शामिल है।

एम्स, भोपाल नेशनल नॉलेज नेटवर्क (एनकेएन) का एक सहयोगी भागीदार है जिसमें इस क्षेत्र की अद्यतन जानकारी साझा करने के लिए पूरे देश में 52 मेडिकल कॉलेज जुड़े है। देश के जरूरत मंद लोगो को गुणवत्तापूर्ण स्वास्थ्य देखभाल सेवा उपलब्ध कराने के लिए लागू भारत सरकार की आयुष्मान भारत योजना के तहत प्रधान मंत्री जन आरोग्य योजना भी एम्स भोपाल में आरंभ की गई है।

यह किसी भी एम्स में पहली बार है कि एम्स भोपाल में ट्रांसलेशनल मेडिसिन के लिए एक अलग केंद्र स्थापित किया गया है। इस केन्द्र में समर्पित संकाय सदस्य तथा होल जीनोम सीक्वेंसर औटोमटेड न्यूक्लिक एसिड एक्स्ट्रक्टर जैसे उपकरणो के साथ अत्याधुनिक बुनयादी सुविधाए उपलब्ध होगी। पशुओं पर ड्रग एवं वेक्सीन के परीक्षण के लिए फ्लो साइटोमीटर एटोमिक एबजोर्बसन सिस्टम तथा इन-विवो-इमेज एनालाइजर। संकाय के लिए यह आवश्यक होगा कि वे नए डायग्नोस्टिक तथा मानव डिवाइसेस, ड्रग्स, वैक्सीन तथा आर्टिफिशियल इंटेलीजेंस (कृत्रिम बुद्धिमती) पर आधारित प्रणालियों का विकास करें। यहां उल्लेख करना महत्वपूर्ण होगा कि संस्थान ने सी एंड डीएसटी-टी.बी. लेबोरेटरी के साथ-साथ रीजनल वायरोलाजी डायग्नोस्टिक लेबोरेटरी (आरवीडीएल) प्रारंभ की है जो राज्य में इस तरह की पहली लेबोरेटरी है। एक 16 बैड का एम.डी.आर. वार्ड भी प्रस्तावित है। समग्र दृष्टिकोण अपनाते हुए संस्थान ने एम्स, नई दिल्ली के साथ मिलकर एक कैंसर उपचार केन्द्र की स्थापना की है। हाल ही में, एम्स, भोपाल ने एक कैंसर पंजीयन केन्द्र (Cancer Registration Center) तथा विष सूचना केन्द्र (Poison Information Center) (पी. आई. सी.) की स्थापना भी की है।

संस्थान ने नए स्थापित सभी एम्स से आगे बढ़ते हुए अनुसंधान गतिविधियों में सामंजस्य के लिए एक समर्पित अनुसंधान सेल की स्थापना की है। पिछले दो वर्षों में कुल 233 पब्लिकेशन हुए है। एम्स, भोपाल के संकाय विशेषतः ट्यूबरक्यूलोसिस, कैंसर परीक्षण, संक्रामक बीमारियों, क्रोनिक किडनी डिसीजों, पर्यावरण टाक्सीन, हेल्थ केयर डिलेवरी सिस्टम, गंभीर कुपोषण, स्वास्थ्य पर योग का प्रभाव, मेडिटेशन तथा एंटीमाइक्रोबियल स्टीवर्डशिप इत्यादि पर चुनौतीपूर्ण अनुसंधान कर रहे है। भारत सरकार के स्वास्थ्य एवं परिवार कल्याण मंत्रालय तथा मध्यप्रदेश सरकार ने एम्स भोपाल को कोविड-19 अनुसंधान के लिए उत्कृष्ट केन्द्र का दर्जा दिया है। संस्थान कोविड-19 ट्रीटमेंट के लिए माइक्रोबैक्टिरियम डब्ल्यू (एम डब्ल्यू) क्लीनिकल ट्रायल शुरु करने वाला पहला संस्थान है। एम्स, भोपाल के संकाय द्वारा पिछले एक वर्ष में विभिन्न फडिंग एजेंसियों को बाहरी फंडिग के लिए कुल 180 रिसर्च प्रपोजल प्रस्तुत किए गए थे। इनमें से 45 प्रोजेक्टस फंडिंग के लिए अनुमोदित किए गए। इन एजेंसियों से प्रतिष्ठित फडिंग एजेंसियों में आईसीएमआर, डीएसटी, डीबीटी, बीआईआरएसी, डीएचआर, यूनिसेफ, मध्य प्रदेश सरकार शामिल है। इस अवधि में इन परियोजनाओं के लिए कुल अनुदान की राशि 25.11 करोड़ रुपये है। शासकीय धन आबंटन से सेंटर ऑफ एक्सीलेंस इन लेबर डिलीवरी एंड रिकवरी (एलडीआर) तथा एजीस ऑफ इंडियन फार्माकोपिया कमीशन, गाजियाबाद के अधीन फार्माकोलाजी विभाग में मेडिकल डिवाइस एडवर्स इवेंट मानीटरिंग सेंटर की स्थापना की गई है। संस्थान ने अनुसंधान गतिविधियों को बढ़ावा देने के उद्देश्य से अल्पकालिक अवधि के लिए अपनी प्रयोगशाला सुविधाएं उपलब्ध कराना प्रारंभ किया है।

एम्स, भोपाल संस्थान अपने अथक प्रयासों से पीएसयू के साथ-साथ निजी संगठनों से बड़ी मात्रा में सीएसआर फडिंग हासिल करने में सफल हुआ है। जिसका उपयोग एम्स, भोपाल में अत्याधुनिक उपकरणों, उच्च कोटि की केन्द्रित सुविधाओं की स्थापना में किया जाएगा।

अंत में, जैसा कि हम नए दशक 2020 में प्रवेश कर रहे है तो हमारे लिए यह समय है कि हम अपने शब्दों को कार्य में तब्दील करें और इसी क्रम में एम्स, भोपाल में मेडिकल कॉलेज भवन का विस्तार, सीएस के माध्यम से रोगी देखभाल सेवा हेतु 200 से 250 बिस्तरों के विश्राम सदन का विस्तार, बहुपयोगी हॉल के साथ इंडोर स्पोर्ट्स काम्प्लेक्स का विस्तार, विभिन्न श्रेणियों के आवास हेतु आवासीय काम्प्लेक्स के फेस-II का निर्माण, मनोरंजन पार्क का विकास, हर्बल गार्डन परिसर को अधिक हरा भरा बनाना, जल संसाधन क्षमता को बढ़ाकर जल संसाधन में संस्थान को आत्मनिर्भर बनाना, ऊर्जा संरक्षण को बढ़ाना, जन स्वास्थ्य विद्यालय के साथ चिकलोद में ग्रामीण स्वास्थ्य केन्द्र की स्थापना तथा अन्य अनेक विकास कार्यों के अलावा कॉर्पोरेट सोशल रिस्पॉन्सिबिलिटी फ़ंड से एक अंतर्राष्ट्रीय वैक्सीन साइंसेज सेंटर की स्थापना किया जाना है।

मुझे एम्स, भोपाल का भविष्य अत्यंत उज्ज्वल और संस्थान में असीम संभावनाएं नजर आ रही है। मुझे पूर्ण विश्वास है कि हम रोगियों, मानव सेवा एवं राष्ट्र के प्रति हमारे सभी संकल्पों को दृढ़ इच्छाशक्ति के साथ पूरा करने के लिए अपने समर्पण एवं अथक प्रयासों को निरंतर जारी रखेंगे।

प्रो. सरमन सिंह

निदेशक एवं मुख्य कार्यपालक अधिकारी

एम्स भोपाल